Takeda

Takeda is known as a global pharmaceutical company that develops life-transforming medicines and therapies in its focus areas of oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines. With a history dating back over 200 years, Takeda is recognized for its strong focus on research and development, strategic acquisitions like the takeover of Shire Plc, and its efforts to improve access to medicine and health care in emerging markets. Takeda is a research-driven biopharmaceutical company, heavily investing in R&D to discover and deliver innovative treatments. The company's R&D efforts focus on specific areas to cultivate expertise and accelerate the development of life-transforming medicines for patients.

Takeda's key therapeutic areas of focus include oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines.

Yes, Takeda is considered a 'big pharma' company. It is Japan's largest drugmaker and one of the top pharmaceutical companies in the world by revenue, a ranking that rose significantly following its merger with Shire. Takeda is a leading global biopharmaceutical company with a significant presence worldwide. The company's substantial acquisition of Shire was a major move that increased its size and global impact. Takeda invests heavily in research and development and is known for developing life-transforming treatments.

Entyvio is frequently cited as Takeda's top-selling drug. It is a biologic therapy primarily used for the treatment of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease.

Amid a broader profit decline catalyzed by patent losses, Takeda restructured. In the process, the company cut a series of programs for solid tumors and blood cancers and pivoted to autoimmune conditions, as many other cell therapy developers have amid a tough funding climate.